Results 111 to 120 of about 2,336 (164)
Recent Advances in Lipopolysaccharide-Based Glycoconjugate Vaccines [PDF]
Expert Review of Vaccines, 2021 The public health burden caused by pathogenic Gram-negative bacteria is increasingly prominent due to antimicrobial resistance. The surface carbohydrates are potential antigens for vaccines against Gram-negative bacteria. The enhanced immunogenicity of the O-specific polysaccharide (O-SP) moiety of LPS when coupled to a carrier protein may protect ...
Andrew J. Pollard +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Glycoconjugate vaccines: an update
Expert Opinion on Biological Therapy, 2014Globally, the three main pathogens causing serious infections are Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis. Over the last 5 years, new vaccines protecting against these bacteria have been developed and introduced in various countries.This review describes the recently licensed glycoconjugates being used to ...
Mairi, Vella, David, Pace
openaire +2 more sources
Expert Opinion on Biological Therapy, 2012
The global disease burden of serious bacterial infections is caused mainly by Haemophilus influenzae type b (Hib), Streptococcus pneumoniae and Neisseria meningitidis. Death or disability may be the potential aftermath of invasive infections with these pathogens.
openaire +2 more sources
The global disease burden of serious bacterial infections is caused mainly by Haemophilus influenzae type b (Hib), Streptococcus pneumoniae and Neisseria meningitidis. Death or disability may be the potential aftermath of invasive infections with these pathogens.
openaire +2 more sources
Designing a new antifungal glycoconjugate vaccine
Chem. Soc. Rev., 2013Bacterial capsular polysaccharides have been used as effective vaccines for adults but infants and seniors respond poorly to these immunogens because pure polysaccharides are unable to activate T-cells resulting in antibodies of low affinity and poor immunological memory.
Margaret A, Johnson, David R, Bundle
openaire +2 more sources
Glycoconjugate vaccines and immune interference: A review
Vaccine, 2010Bacterial polysaccharide-protein conjugate vaccines (Haemophilus influenzae type b [Hib], pneumococcal and meningococcal conjugates) have revolutionized pediatric vaccination strategies. The widely used carrier proteins are tetanus toxoid (TT), diphtheria toxoid (DT) and diphtheria toxoid variant CRM197 protein, DT conjugates being in general less ...
Dagan, Ron +2 more
openaire +2 more sources
Glycoconjugate vaccines: Principles and mechanisms
Science Translational Medicine, 2018Insight into the mechanisms of glycoconjugate vaccines can improve their efficacy and impact in the future.
openaire +2 more sources
Glycoconjugate Vaccines: What Next?
International Journal of Technology Assessment in Health Care, 1994AbstractThe principle that infants can be protected from invasive diseases caused by encapsulated organisms has been proved with the introduction ofHaemophilus influenzaetype b conjugate vaccines. The use of glycoconjugates to implement some of the goals of the Children's Vaccine Initiative requires a clear delineation of the chemical and immunological
openaire +2 more sources
Current opinion in drug discovery & development, 2011
Licensed glycoconjugate vaccines provide protective immunity against bacterial pathogens by eliciting a T-cell-dependent immune response to the corresponding bacterial saccharide covalently linked to a protein carrier. The field is rapidly expanding to include the introduction of novel carrier proteins and conjugation chemistries, the development of ...
N, Ravenscroft, C, Jones
openaire +1 more source
Licensed glycoconjugate vaccines provide protective immunity against bacterial pathogens by eliciting a T-cell-dependent immune response to the corresponding bacterial saccharide covalently linked to a protein carrier. The field is rapidly expanding to include the introduction of novel carrier proteins and conjugation chemistries, the development of ...
N, Ravenscroft, C, Jones
openaire +1 more source
Recent advances in self-adjuvanting glycoconjugate vaccines
Drug Discovery Today: Technologies, 2020Compared to traditional vaccines that are formulated into mixtures of an adjuvant and an antigen, a self-adjuvanting vaccine consists of an antigen that is covalently conjugated to a well-defined adjuvant. In self-adjuvanting vaccines, innate immune receptor ligands are usually used as adjuvants.
Yoshiyuki, Manabe +2 more
openaire +2 more sources
Glycoconjugate Vaccines: The Regulatory Framework
2015Most vaccines, including the currently available glycoconjugate vaccines, are administered to healthy infants, to prevent future disease. The safety of a prospective vaccine is a key prerequisite for approval. Undesired side effects would not only have the potential to damage the individual infant but also lead to a loss of confidence in the respective
openaire +2 more sources